Nakayama, Turrent robert

写真a

Affiliation

School of Medicine, Department of Orthopaedic Surgery (Shinanomachi)

Position

Assistant Professor/Senior Assistant Professor

External Links
Page Top ▲

Academic Background 【 Display / hide 】

  • 1995.04
    -
    2001.03

    慶應義塾大学, 医学部, 医学科

    University, Graduated

  • 2004.04
    -
    2008.03

    慶應義塾大学, 医学部, 医学科

    Graduate School, Graduated, Doctoral course

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 医学博士, 慶應義塾大学, 2008.01

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 医師免許, 2001.05

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Orthopedics

Page Top ▲

Research Keywords 【 Display / hide 】

  • Musculoskeletal Oncology

Page Top ▲
 

Papers 【 Display / hide 】

  • Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib

    Endo M., Kataoka T., Fujiwara T., Tsukushi S., Takahashi M., Kobayashi E., Yamada Y., Tanaka T., Nezu Y., Hiraga H., Wasa J., Nagano A., Nakano K., Nakayama R., Hamada T., Kawano M., Torigoe T., Sakamoto A., Asanuma K., Morii T., Machida R., Sekino Y., Fukuda H., Oda Y., Ozaki T., Tanaka K.

    BMC Cancer (BMC Cancer)  23 ( 1 )  2023.12

    　View Summary

    Background: Soft tissue sarcomas (STS) are a rare type of malignancy comprising a variety of histological diagnoses. Chemotherapy constitutes the standard treatment for advanced STS. Doxorubicin-based regimens, which include the administration of doxorubicin alone or in combination with ifosfamide or dacarbazine, are widely accepted as first-line chemotherapy for advanced STS. Trabectedin, eribulin, pazopanib, and gemcitabine plus docetaxel (GD), which is the empirical standard therapy in Japan, are major candidates for second-line chemotherapy for advanced STS, although clear evidence of the superiority of any one regimen is lacking. The Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group (JCOG) conducts this trial to select the most promising regimen among trabectedin, eribulin, and pazopanib for comparison with GD as the test arm regimen in a future phase III trial of second-line treatment for patients with advanced STS. Methods: The JCOG1802 study is a multicenter, selection design, randomized phase II trial comparing trabectedin (1.2 mg/m2 intravenously, every 3 weeks), eribulin (1.4 mg/m2 intravenously, days 1 and 8, every 3 weeks), and pazopanib (800 mg orally, every day) in patients with unresectable or metastatic STS refractory to doxorubicin-based first-line chemotherapy. The principal eligibility criteria are patients aged 16 years or above; unresectable and/or metastatic STS; exacerbation within 6 months prior to registration; histopathological diagnosis of STS other than Ewing sarcoma, embryonal/alveolar rhabdomyosarcoma, well-differentiated liposarcoma and myxoid liposarcoma; prior doxorubicin-based chemotherapy for STS, and Eastern Cooperative Oncology Group performance status 0 to 2. The primary endpoint is progression-free survival, and the secondary endpoints include overall survival, disease-control rate, response rate, and adverse events. The total planned sample size to correctly select the most promising regimen with a probability of > 80% is 120. Thirty-seven institutions in Japan will participate at the start of this trial. Discussion: This is the first randomized trial to evaluate trabectedin, eribulin, and pazopanib as second-line therapies for advanced STS. We endeavor to perform a subsequent phase III trial comparing the best regimen selected by this study (JCOG1802) with GD. Trial registration: This study was registered with the Japan Registry of Clinical Trials (jRCTs031190152) on December 5, 2019.

  • Dedifferentiated liposarcoma in the extremity and trunk wall: A multi-institutional study of 132 cases by the Japanese Musculoskeletal Oncology Group (JMOG)

    Morii T., Anazawa U., Sato C., Iwata S., Nakagawa M., Endo M., Nakamura T., Ikuta K., Nishida Y., Nakayama R., Udaka T., Kawamoto T., Kito M., Sato K., Imanishi J., Akiyama T., Kobayashi H., Nagano A., Outani H., Toki S., Nishisho T., Sasa K., Suehara Y., Kawano H., Ueda T., Morioka H.

    European Journal of Surgical Oncology (European Journal of Surgical Oncology)  49 ( 2 ) 353 - 361 2023.02

    ISSN  07487983

    　View Summary

    Background: Dedifferentiated liposarcoma occurs predominantly in the retroperitoneum. Given the paucity of cases, information on the clinical characteristics of this entity in the extremities and trunk wall is quite limited. In particular, the significance of preoperative evaluation and principles of intraoperative management of the different components, i.e., well-differentiated and dedifferentiated areas, are still to be defined. Methods: Clinical characteristics, treatment outcomes, and risk factors for poor oncological outcomes in cases of dedifferentiated liposarcoma in the extremity or trunk wall were analyzed by a retrospective, multicentric study. Results: A total of 132 patients were included. The mean duration from the initial presentation to dedifferentiation was 101 months in dedifferentiation-type cases. The 5-year local recurrence-free survival, metastasis-free survival, and disease-specific survival rates were 71.6%, 75.7%, and 84.7%, respectively. Among 32 patients with metastasis, 15 presented with extrapulmonary metastasis. A percentage of dedifferentiated area over 87.5%, marginal/intralesional margin, and R1/2 resection in the dedifferentiated area were independent risk factors for local recurrence. Dedifferentiated areas over 36 cm2, French Federation of Cancer Centers Sarcoma Group grade III, and intralesional or marginal resection were independent risk factors for metastasis. A dedifferentiated area over 77 cm2 and lung metastasis were independent risk factors for disease-specific mortality. Conclusions: The typical clinical characteristics of dedifferentiated liposarcoma in the extremity and trunk wall were reconfirmed in the largest cohort ever. The evaluation of the dedifferentiated area in terms of grade, extension, and pathological margin, together with securing adequate surgical margins, was critical in the management of this entity.

  • Recurrent malignant peripheral nerve sheath tumor presenting as an asymptomatic intravenous thrombus extending to the heart: a case report

    Hirozane T., Nakayama R., Yamaguchi S., Mori T., Asano N., Asakura K., Kikuta K., Kawaida M., Sasaki A., Okita H., Nakatsuka S., Ito T.

    World Journal of Surgical Oncology (World Journal of Surgical Oncology)  20 ( 1 )  2022.12

    　View Summary

    Background: Malignant peripheral nerve sheath tumor (MPNST) is a rare soft tissue sarcoma mainly treated via surgical resection. Herein, we report a case of MPNST wherein a massive tumor thrombus extended to the major veins and heart. Case presentation: A 39-year-old female with a history of neurofibromatosis type 1 developed MPNST from the right radial nerve. In addition to adjuvant chemotherapy, she underwent wide tumor resection and concomitant radial nerve resection, followed by postoperative radiotherapy. Histological evaluation revealed marked venous invasion. The 2-year follow-up CT revealed an asymptomatic recurrent tumor thrombus extending from the right subclavian vein to the heart. An urgent life-saving operation was performed to ligate the base of the right subclavian vein and remove the entire intravenous thrombus that extended to the right ventricle. The remaining tumor in the right subclavian vein increased in size 3 months after thrombectomy. After confirming the absence of any metastatic lesions, the patient underwent extended forequarter amputation to achieve surgical remission. One year later, a new metastasis to the right diaphragm was safely resected. The patient remains alive without any evidence of disease 2 years after the extended forequarter amputation. Conclusions: In cases of a previous history of microscopic venous invasion, recurrence can occur as a massive tumor thrombus that extends to the great vessels.

  • Standardization of evaluation method and prognostic significance of histological response to preoperative chemotherapy in high-grade non-round cell soft tissue sarcomas

    Oda Y., Tanaka K., Hirose T., Hasegawa T., Hiruta N., Hisaoka M., Yoshimoto M., Otsuka H., Bekki H., Ishii T., Endo M., Kunisada T., Hiruma T., Tsuchiya H., Katagiri H., Matsumoto Y., Kawai A., Nakayama R., Kawashima H., Takenaka S., Emori M., Watanuki M., Yoshida Y., Okamoto T., Mizusawa J., Fukuda H., Ozaki T., Iwamoto Y., Nojima T.

    BMC Cancer (BMC Cancer)  22 ( 1 )  2022.12

    　View Summary

    Background: Preoperative chemotherapy is widely applied to high-grade localized soft tissue sarcomas (STSs); however, the prognostic significance of histological response to chemotherapy remains controversial. This study aimed to standardize evaluation method of histological response to chemotherapy with high agreement score among pathologists, and to establish a cut-off value closely related to prognosis. Methods: Using data and specimens from the patients who had registered in the Japan Clinical Oncology Group study, JCOG0304, a phase II trial evaluating the efficacy of perioperative chemotherapy with doxorubicin (DOX) and ifosfamide (IFO), we evaluated histological response to preoperative chemotherapy at the central review board. Results: A total of 64 patients were eligible for this study. The percentage of viable tumor area ranged from 0.1% to 97.0%, with median value of 35.7%. Regarding concordance proportion between pathologists, the weighted kappa coefficient (κ) score in all patients was 0.71, indicating that the established evaluation method achieved substantial agreement score. When the cut-off value of the percentage of the residual tumor area was set as 25%, the p-value for the difference in overall survival showed the minimum value. Hazard ratio of the non-responder with percentage of the residual tumor < 25%, to the responder was 4.029 (95% confidence interval 0.893–18.188, p = 0.070). Conclusion: The standardized evaluation method of pathological response to preoperative chemotherapy showed a substantial agreement in the weighted κ score. The evaluation method established here was useful for estimating of the prognosis in STS patients who were administered perioperative chemotherapy with DOX and IFO. Trial registration: UMIN Clinical Trials Registry C000000096. Registered 30 August, 2005 (retrospectively registered).

  • Short-term clinical outcomes of Kyocera Modular Limb Salvage System designed cementless stems for the endoprosthetic reconstruction of lower extremities: a Japanese Musculoskeletal Oncology Group multi-institutional study

    Tsukushi S., Nishida Y., Hirose T., Nakata E., Nakagawa R., Nakamura T., Imanishi J., Nagano A., Tamiya H., Ueda T., Ikuta K., Kawai A., Kunisada T., Nakayama R., Torigoe T., Takenaka S., Kakunaga S., Kawano H., Shirai T., Terauchi R., Outani H., Nishimura S., Honoki K.

    BMC Cancer (BMC Cancer)  22 ( 1 )  2022.12

    　View Summary

    Background: The high rate of aseptic loosening of cemented stems has led to their frequent use in endoprosthetic reconstruction. However, problems, such as stem breakage and stress shielding at the insertion site, remain. The Japanese Musculoskeletal Oncology Group (JMOG) has developed Kyocera Modular Limb Salvage System (KMLS) cementless stems with a unique tapered press-fit and short fixation design. This study aimed to clarify the short-term postoperative outcomes of this prosthesis and validate the stem design. Methods: One hundred cases of KMLS cementless stems (51 male patients; median age, 49 years; mean follow-up period, 35 months), with a minimum follow-up of 2 years, for the proximal femur (PF), distal femur (DF), and proximal tibia were prospectively registered for use. Prosthesis survival, complication rates, postoperative functional, and radiographical evaluation were analyzed. Complications or failures after insertion of the KMLS endoprostheses were classified into five types and functional results were analyzed according to the MSTS scoring system at postoperative 1 year. The diaphyseal interface and anchorage were graded by the ISOLS system at postoperative 2 years. Results: The overall prosthesis survival rates at 2 and 4 years were 88.2 and 79.6%, respectively. The prosthesis-specific survival rate excluding infection and tumor recurrence was 90.2 and 87.9%, respectively. Younger age (p = 0.045) and primary tumor (p = 0.057) were associated with poor prognosis of prosthesis-specific survival excluding infection and tumor recurrence. Complications were observed in 31 patients, 13 patients underwent revision surgery. The mean MSTS functional score at 1 year postoperatively was 68%. Early implant loosening was significantly more common in the DF (p = 0.006) and PF/DF straight stem (p = 0.038). The ISOLS radiographic evaluation at 2 years after surgery revealed good bone remodeling and anchorage in most cases (bone remodeling: 90% / excellent and good, anchorage: 97% / excellent and good). Conclusions: Tumor endoprosthesis long-term fixation to the diaphysis of the lower extremity remains challenging. The KMLS cementless stem with a unique tapered press fit design showed good short-term results in maintaining bone stock. To prevent early loosening, a curved stem should be used in PF and DF, but long-term follow-up is necessary.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • Congenital dermatofibrosarcoma protuberans presenting as a depressed plaque: Clinical presentation and chronology

    Nakajima Y., Fusumae T., Hirai I., Nakamura Y., Mori T., Nakayama R., Tsuchiya M., Hashimoto R., Funakoshi T.

    Journal of Dermatology (Journal of Dermatology)  50 ( 4 ) e127 - e128 2023.04

    ISSN  03852407

  • Potocki-Shaffer syndrome revealed in a WAGR syndrome case with multiple exostoses

    Yaga T., Iguchi A., Nakayama R., Kosaki R., Ishiguro A.

    Pediatrics International (Pediatrics International)  65 ( 1 )  2023.01

    ISSN  13288067

  • Correction to: Indications for fertility preservation not included in the 2017 Japan Society of Clinical Oncology Guideline for Fertility Preservation in Pediatric, Adolescent, and Young Adult Patients treated with gonadal toxicity, including benign diseases (International Journal of Clinical Oncology, (2022), 27, 2, (301-309), 10.1007/s10147-021-02082-9)

    Ono M., Matsumoto K., Boku N., Fujii N., Tsuchida Y., Furui T., Harada M., Kanda Y., Kawai A., Miyachi M., Murashima A., Nakayama R., Nishiyama H., Shimizu C., Sugiyama K., Takai Y., Fujio K., Morishige K.I., Osuga Y., Suzuki N.

    International Journal of Clinical Oncology (International Journal of Clinical Oncology)  27 ( 4 ) 825 - 826 2022.04

    ISSN  13419625

    　View Summary

    The article, Indications for fertility preservation not included in the 2017 Japan Society of Clinical Oncology Guideline for Fertility Preservation in Pediatric, Adolescent, and Young Adult Patients treated with gonadal toxicity, including benign diseases written by Masanori Ono, Kimikazu Matsumoto, Narikazu Boku, Nobuharu Fujii, Yumi Tsuchida, Tatsuro Furui, Miyuki Harada, Yoshinobu Kanda, Akira Kawai, Mitsuru Miyachi, Atsuko Murashima, Robert Nakayama, Hiroyuki Nishiyama, Chikako Shimizu, Kazuhiko Sugiyama, Yasushi Takai, Keishi Fujio, Ken‑Ichirou Morishige, Yutaka Osuga, and Nao Suzuki was originally published Online First without Open Access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on February 16, 2022 to © Author(s) 2021 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0. The original article has been corrected.

  • Correction to: Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 2 (International Journal of Clinical Oncology, (2022), 27, 2, (281-300), 10.1007/s10147-021-02076-7)

    Tozawa A., Kimura F., Takai Y., Nakajima T., Ushijima K., Kobayashi H., Satoh T., Harada M., Sugimoto K., Saji S., Shimizu C., Akiyama K., Bando H., Kuwahara A., Furui T., Okada H., Kawai K., Shinohara N., Nagao K., Kitajima M., Suenobu S., Soejima T., Miyachi M., Miyoshi Y., Yoneda A., Horie A., Ishida Y., Usui N., Kanda Y., Fujii N., Endo M., Nakayama R., Hoshi M., Yonemoto T., Kiyotani C., Okita N., Baba E., Muto M., Kikuchi I., Morishige K.i., Tsugawa K., Nishiyama H., Hosoi H., Tanimoto M., Kawai A., Sugiyama K., Boku N., Yonemura M., Hayashi N., Aoki D., Suzuki N., Osuga Y.

    International Journal of Clinical Oncology (International Journal of Clinical Oncology)  27 ( 3 ) 635 - 637 2022.03

    ISSN  13419625

    　View Summary

    The article, Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 2 written by Akiko Tozawa, Fuminori Kimura, Yasushi Takai, Takeshi Nakajima, Kimio Ushijima, Hiroaki Kobayashi, Toyomi Satoh, Miyuki Harada, Kohei Sugimoto, Shigehira Saji, Chikako Shimizu, Kyoko Akiyama, Hiroko Bando, Akira Kuwahara, Tatsuro Furui, Hiroshi Okada, Koji Kawai, Nobuo Shinohara, Koichi Nagao, Michio Kitajima, Souichi Suenobu,Toshinori Soejima, Mitsuru Miyachi, Yoko Miyoshi, Akihiro Yoneda, Akihito Horie,Yasushi Ishida, Noriko Usui, Yoshinobu Kanda, Nobuharu Fujii, Makoto Endo, Robert Nakayama, Manabu Hoshi, Tsukasa Yonemoto, Chikako Kiyotani, Natsuko Okita, Eishi Baba, Manabu Muto, Iwaho Kikuchi, Ken‑ichirou Morishige, Koichiro Tsugawa, Hiroyuki Nishiyama, Hajime Hosoi, Mitsune Tanimoto, Akira Kawai, Kazuhiko Sugiyama, Narikazu Boku, Masato Yonemura, Naoko Hayashi, Daisuke Aoki, Nao Suzuki, Yutaka Osuga was originally published Online First without Open Access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on February 14, 2022 to © Author(s) 2021 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0. The original article has been corrected.

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • リキッドバイオプシーによる骨軟部腫瘍の病勢モニタリングの実用化を目指した研究

    2021.04
    -
    2024.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

  • 滑膜肉腫における変異SWI/SNFクロマチン制御複合体の機能解析

    2017.04
    -
    2020.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • MEDICAL ONCOLOGY

    2025

  • LECTURE SERIES, ORTHOPAEDICS

    2025

  • LECTURE SERIES, ORTHOPAEDICS

    2024

  • LECTURE SERIES, ORTHOPAEDICS

    2023

  • LECTURE SERIES, ORTHOPAEDICS

    2022

display all >>

Page Top ▲